Beland Khalil

Ma1709o

A new clinical trial was conducted introducing a new

“Atrovastatin” to lower the levels of triglycerides and their
Body Mass Indexes (BMI) , in hopes of lowering their
weight and stubborn belly fat caused by a high cholesterol
diet. ​A total of 8 participants are randomized to receive
either the new drug or a placebo. Participants are asked to
record their body mass index over a period of 3 months.

The null hypothesis H0​ : all participants in the clinical

trial, those who took the drug and those who took the
placebo, have the same Body mass index.

The alternative hypothesis H1​ : participants that have

taken the drug have a lower BMI than those who have
taken a placebo.
Drug 34 31 33 32
Placebo 36 35 34 37

Total Rank
sample
Drug Placebo Drug Placeb Drug Placebo
o
34 36 31 1
31 35 32 2
33 34 33 3
32 37 34 34 4.5 4.5
35 6
36 7
37 8